Fig 1.
Flow chart displaying selection of study participants for analysis.
Out of 289 patients with biopsy proven NASH by transjugular liver biopsy, 32 were excluded for inadequate biopsy specimen. After further exclusion of patients with missing data, those with anti-HCV or HBsAg positivity, patients with significant alcohol intake, the ones with decompensated cirrhosis at entry and patients with insufficient follow-up, the remaining sample of 148 consecutive patients with NASH was included in the present study.
Table 1.
Demographic, clinical and histological characteristics of 148 patients with NASH at baseline and comparison of those with and without clinical outcomes.
Table 2.
Incidence rates of clinical outcomes according to fibrosis and risk category defined by non-invasive tools, liver histology and HVPG.
Fig 2.
Survival curves of probability of clinical outcomes by: (A) APRI fibrosis category; (B) FIB-4 fibrosis category; (C) NAFLD fibrosis score category.
Fig 3.
Survival curves of probability of clinical outcomes by: (A) HVPG category; (B) histologic fibrosis category.
Table 3.
Multivariate hazard ratios of clinical outcomes by high-risk fibrosis category.
Table 4.
AUC, accuracy, sensitivity, specificity, predictive values, likelihood ratios of baseline liver histology, HVPG and non-invasive fibrosis biomarkers to predict clinical outcomes.
Fig 4.
AUC of HVPG, histologic fibrosis stage, APRI, FIB-4 and NAFLD fibrosis score for prediction of clinical outcomes.